Optimal Dosing of IC-Green for Visualization of Rotator Cuff Vascularity Using Advanced Imaging Modality Arthroscopy
Rotator Cuff Tears
About this trial
This is an interventional treatment trial for Rotator Cuff Tears
Eligibility Criteria
Inclusion Criteria:
- Patients has full or partial thickness rotator cuff tear and is scheduled to undergo arthroscopic rotator cuff repair
- Patient is at least 18 years of age and less than 80 years of age
Exclusion Criteria:
- Patient is less than 18 years of age or greater than 79 years of age
- Patient has a documented allergy to iodides
- Patients who have had iodide based radiology studies within the last seven (7) days prior to surgery
- Patient is pregnant
Sites / Locations
- NYU Langone HealthRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Group 1:ICG 7.5 mg
Group 2:ICG 12.5 mg
Group 3: ICG 25 mg
Subjects in this group are randomized to receive 7.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
Subjects in this group are randomized to receive 12.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
Subjects in this group are randomized to receive 25 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.